دورية أكاديمية

Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial

التفاصيل البيبلوغرافية
العنوان: Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial
المؤلفون: Annala, M., Fu, S., Bacon, J.V.W., Sipola, J., Iqbal, N., Ferrario, C., Ong, M., Wadhwa, D., Hotte, S.J., Lo, G., Tran, B., Wood, L.A., Gingerich, J.R., North, S.A., Pezaro, C.J., Ruether, J.D., Sridhar, S.S., Kallio, H.M.L., Khalaf, D.J., Wong, A., Beja, K., Schönlau, E., Taavitsainen, S., Nykter, M., Vandekerkhove, G., Azad, A.A., Wyatt, A.W., Chi, K.N.
المصدر: In Annals of Oncology July 2021 32(7):896-905
قاعدة البيانات: ScienceDirect
الوصف
تدمد:09237534
DOI:10.1016/j.annonc.2021.03.205